Back to Search
ARTHUR SANTORA, MD, PHD
MD, PHD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1952474520IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
25MA05409600(NJ)
CMS Specialties
PrimaryENDOCRINOLOGY
Education
OTHER
Class of 1978
Research & Publications (20)
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.
PMID 18544475·Bone·2008
6-review
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
PMID 19185560·Bone·2009
4-observational
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
PMID 17190893·JAMA·2006
4-observational
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
PMID 16968578·Curr Med Res Opin·2006
3-trial
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
PMID 16418785·J Bone Miner Res·2006
2-rct
Are we treating women with postmenopausal osteoporosis for their low BMD or high fracture risk?
PMID 16234982·J Bone Miner Res·2005
8-other
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study.
PMID 16133688·J Bone Miner Metab·2005
3-trial
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women.
PMID 15801989·Curr Med Res Opin·2005
3-trial
Osteoporosis and fracture risk in women of different ethnic groups.
PMID 15647811·J Bone Miner Res·2005
8-other
Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.
PMID 15472179·J Clin Endocrinol Metab·2004
3-trial
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
PMID 15231012·J Bone Miner Res·2004
3-trial
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
PMID 15028823·N Engl J Med·2004
3-trial
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
PMID 13678475·Curr Med Res Opin·2003
3-trial
Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis.
PMID 12681875·Obstet Gynecol·2003
3-trial
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment.
PMID 12469916·J Bone Miner Res·2002
8-other
Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
PMID 12412806·J Bone Miner Res·2002
3-trial
Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.
PMID 12050252·J Clin Endocrinol Metab·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 125 PATERSON ST, CLINICAL ACADEMIC BUILDING - SUITE 5100A
NEW BRUNSWICK, NJ 08901 - Phone
- (732) 235-7219
Quick Facts
- NPI
- 1952474520
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 48
- Publications
- 20
Are you this provider?
Claim Your Profile